uniQure sells Lexington manufacturing facility to Genezen for $25M, reduces cash burn $40M/year

uniQure N.V.

Consideration $25M: $12.5M of Series C preferred stock and $12.5M convertible note (8%, 63-month maturity).
Genezen to manufacture HEMGENIX commercial supply; CEO Matt Kapusta joins Genezen board after close.
Company expects to reduce annual cash burn by ~$40M and repay $50M debt, saving interest expense.
Majority of Lexington employees offered jobs at Genezen; transaction expected to close early Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.